“Gyrolab enabled us to improve our measurement accuracy and reliability over other platforms which had high background signal and poor sensitivity.”
SNBL is proud to have over five decades of experience as a contract research organization, and we use that experience to work with our clients to meet their drug development needs. In our time in business, we have been able to find the essential balance between speed and reliability.
We maintain this balance by building close cooperative relationships with our clients. Delivering high quality study data promptly is something we take pride in. We offer comprehensive services and expertise from the early preclinical phase of efficacy and safety of new compounds up to Phase IV clinical studies of commercially available new drugs. We are confident that the four pillars of our business, pre-clinical, pharmacokinetics, translational research, and clinical, can benefit clients in any new drug development quest.
SNBL preclinical operations are based at our laboratories, located in Kagoshima and Wakayma, Japan. Preclinical studies are an important part of our drug development research, from screening novel compounds to confirming the safety and efficacy of pharmaceuticals. GLP studies are essential for application to applicable regulatory authorities. With our experienced teams and full-service laboratories, we can custom design a study that is right for most compounds, offering studies described following:
The Wakayama SNBL Pharmacokinetics and Bioanalysis Center (PBC) offers establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters by expert researchers using state-of-the-art equipment. We are able to expertly analyze a number of compounds such as test articles and metabolites in samples, and have conducted more than 8000 studies, by chromatography assay using HPLC, LC-MS/MS, ICP-MS, by ligand binding assay using Gyrolab xP workstation, Meso QuickPlex SQ120, and other instruments. The SNBL PBC can propose the most suitable study design according to client drug development needs, including small, middle, and large molecules.
The SNBL PBC can analyze both preclinical (several kinds of animals) and clinical (Phase I to IV) study samples (plasma, urine, various body fluids, and tissues) in compliance with GxP regulations.
We have been using Gyrolab xP workstation for 7 years to provide commercial services. We offer a broad range of pharmacokinetics analysis and toxicokinetics analysis for biotechnology-based pharmaceuticals including antibody, oligonucleotide, protein, and peptides etc., in biological samples (plasma, serum, urine, etc.) from mouse, rat, monkey, and human.
Advantages of Gyrolab Platform Immunoassays:
We choose Gyrolab when high throughput and high sensitivity analysis methods are necessary.
Investing in Gyrolab Platform for the Future
SNBL originally invested in Gyrolab platform to advance our automation of LBA analysis methods. Gyrolab enabled us to improve our measurement accuracy and reliability over other platforms which had high background signal and poor sensitivity.
The pace of drug development is accelerating, and there is a need to rapidly obtain accurate bioanalysis data. Gyrolab is a powerful tool for increasing the throughput of bioanalysis using immunoassays.
For more information, visit the SNBL website.